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ABSTRACT: Host-defense peptides (HDPs) are promising
compounds against multidrug-resistant microbes. In vitro, their
bactericidal and toxic concentrations are significantly different,
but this might be due to the use of separate assays, with
different cell densities. For experiments with a single cell type,
the cell-density dependence of the active concentration of the
DNS-PMAP23 HDP could be predicted based on the water/
cell-membrane partition equilibrium and exhibited a lower
bound at low cell counts. On the basis of these data, in the
simultaneous presence of both bacteria and an excess of
human cells, one would expect no significant toxicity, but also
inhibition of the bactericidal activity due to peptide
sequestration by host cells. However, this inhibition did not take place in assays with mixed cell populations, showing that
for the HDP esculentin-1a(1−21)NH2, a range of bactericidal, nontoxic concentrations exists and confirming the effective
selectivity of HDPs. Mixed-cell assays might be necessary to effectively asses HDP selectivity.
Host-defense peptides (HDPs) are produced by all livingorganisms as a first defense against pathogens. Multiple
immunomodulatory functions of these peptides have been
described,1 but one of their major activities is bactericidal,
through the perturbation of the membrane permeability of
microbial targets. This mechanism of action makes the
development of bacterial resistance particularly unlikely,2,3
and for this reason these peptides are investigated as lead
compounds to fight multidrug-resistant bacteria, a dramatic and
increasing worldwide threat.4 However, several questions still
limit their clinical applicability.
A major problem is related to HDP selectivity. In vitro, the
majority of HDPs are toxic to mammalian cells only at
concentrations higher than those needed for bactericidal
activity.5 This behavior is presumably determined by the
difference in lipid composition of membranes of the two cell
types, as studies on liposomes show a higher affinity for bilayers
mimicking bacterial membranes.6 However, selectivity might be
just an experimental artifact resulting from the very different
conditions used in assays employed to determine antimicrobial
and hemolytic activities, in particular the cell density.5
Typically, minimal inhibitory concentrations (MICs) are
determined with 5 × 105 to 1 × 106 colony-forming units
(CFUs) per mL, while minimum hemolytic concentrations
(MHCs) are measured in the presence of 5 × 108 cells/mL,5
and red blood cells (RBCs) have a membrane area
approximately 10 times bigger than E. coli cells.7,8 In addition,
the use of separate assays is based on the rather drastic
assumption that the activity of HDPs against a given cell type is
not influenced by the contemporary presence of different cells.
However, in principle, when bacteria are in the presence of an
excess of human cells, the peptide could be inactivated due to
sequestration by host cells. Other important problems relate to
the physiological function of HDPs, i.e. whether the relatively
high peptide concentration needed to kill bacteria can be
reached in vivo and whether their prevalent activity is
bactericidal or immunomodulatory.9 Clarifying all these issues
is essential, since they bear directly on how HDPs are currently
screened and optimized.
A recently blooming approach to tackle these questions
extends to real cells the quantitative physicochemical experi-
ments normally performed on model membranes.10−14
Recently, we measured the association to the membranes of
E. coli cells of a fluorescently labeled analogue of the
cathelicidin HDP PMAP-2315 (DNS-PMAP23, sequence in
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Scheme 1) and determined the threshold value of peptide
molecules that must bind to the membranes of a single cell to
kill it.11 On the basis of these results, in the present work we
theoretically predicted an unexpected behavior of peptide
activity as a function of the density of cells. We also optimized
three assay protocols that allowed us to test experimentally this
prediction by studying the bactericidal and hemolytic activities
in a wide range of cell-density values and to determine both
activities under more realistic conditions, i.e., with both cell
types present at the same time.
The so-called “inoculum effect” is a well-known dependence
of the MIC of traditional antibiotics on the size of the bacterial
inoculum in the growth medium, with the first studies dating
back to the 1940s.16 By contrast, to the best of our knowledge,
the cell-density dependence of HDP activity has not been
investigated before. In a previous study,11 we showed that
association of at least TB = 1.1 × 10
7 DNS-PMAP23 molecules
to the membranes of each cell is needed to cause the death of
99.9% bacteria, i.e., the % reduction in viable cells normally used
to define the minimum bactericidal concentration (MBC).17 In
addition, the measured peptide/cell-membrane association
curves (see Supporting Information [SI], Supporting Figure
1) exhibited a behavior that deviated only slightly from an ideal
partition,11,18,19 where the fraction of membrane-associated
peptide f B dependence on bacterial cell-density ([Bacteria])
can be described according to the following equation, derived
in the SI:
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By fitting the partition curve measured for 10 μM peptide
concentration11 with eq 1, we obtained a value of the apparent
partition constant of Kapp
B = 1.8 × 108 bacterial cells/mL
(Supporting Figure 1). These data allow a calculation of the
fraction of membrane-bound peptide, and thus of the number
of membrane-associated peptides per cell, at any value of
peptide concentration and cell density. On the basis of these
data, we derived an equation (see SI) to predict the minimum
total peptide concentration in the sample able to reach the TB
threshold and thus able to kill 99.9% of the bacteria (i.e., the
MBC)
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Here, NA is Avogadro’s constant, MBC and MBCmin are
expressed in mol/L, Kapp
B and the bacterial cell density
([Bacteria]) are reported in cells/mL, and TB is in molecules
per cell.
The MBC values calculated for DNS-PMAP23, according to
eq 2, are reported as a continuous line in Figure 1b, on a
logarithmic scale. This equation predicts a linear decrease in the
MBC with decreasing cell density. However, it also makes a
rather surprising prediction, i.e., that even when the cell density
becomes extremely low, the MBC does not decrease below a
limiting value, equal to MBCmin (3.3 μM, in our case). This
behavior might seem counterintuitive, because when the cell
density decreases, the total amount of cell-bound peptide
necessary to cause bacterial death diminishes proportionally,
simply because fewer cells need to be killed. Naively, this
consideration would lead to the conclusion that, in the limit of
[Bacteria] → 0, also MBC → 0. However, in the low cell-
density regime, most of the peptide will stay free in solution.
When [Bacteria] ≪ KappB , eq 1, like any hyperbolic equation
(such as a Langmuir binding isotherm or a Michaelis−Menten
enzyme kinetics), can be approximated by linear behavior, and
therefore f B decreases proportionally to [Bacteria]. As a
consequence, the total peptide concentration needed in the
sample to kill the bacteria remains constant (eq 3).
A similar theoretical prediction (i.e., a linear dependence of
MBC, with a nonzero intercept) has been recently reported for
the trend of peptide membrane-perturbing activity with the
concentration of liposomes.20 Those calculations were based on
Scheme 1. Sequences of the Peptides Investigated
Figure 1. Cell-density dependence of DNS-PMAP23 bactericidal
activity. (a) Bactericidal activity in the presence of different E. coli cell
densities. (b) Predicted (eq 2) and experimental cell-density
dependence of the MBC (defined as the concentration that causes
the death of 99.9% of bacteria).
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a complex model considering several aspects of the peptide and
lipid bilayer behavior at the molecular level. By contrast, the
present treatment shows that the predicted trend simply arises
from a close to ideal partition equilibrium, without the need of
any assumptions on molecular level events. In addition, our
previous data on the partition equilibrium and on the value of
the threshold TB
11 allowed us to perform quantitative
predictions in cells.
The behavior predicted by eq 2 was verified by experimental
measurements of MBCs. Figure 1a reports the killing curves
measured in the presence of different cell densities, under the
conditions determined previously,11 where the number of live
bacteria in a control sample remains constant during the time of
the experiment. The interval of cell densities studied was
chosen to cover a realistic range, considering as an upper limit
the number of bacteria in an abscess, which may reach up to 109
bacterial cells per milliliter of pus.21 The behavior predicted
above was actually observed, with the MBC never decreasing
below 3 μM (Figure 1b). The agreement between the
experimental data and the predicted curve (which is not a fit)
was acceptable even quantitatively.
The simple experiment reported here shows that it is
possible to predict the MBC at all cell densities, by determining
the threshold of cell-bound peptides necessary to kill a
bacterium, and the equilibrium of peptide association to
bacterial cells. This possibility was first proposed by Melo et
al. in relation to binding studies on model membranes,22 and it
is now demonstrated with studies on real bacteria. In addition,
our data show that micromolar total peptide concentrations are
necessary to kill the bacteria, even when they are present at low
cell counts. Attaining such concentration values in the body by
systemic administration of HDPs as drugs might prove
problematic. On the other hand, some HDPs can naturally
reach concentrations that are even significantly higher, for
instance in the granules of leukocytes, in the immediate vicinity
of degranulating phagocytes, at the bottom of intestinal crypts,1
in the hemolymph of insects after a bacterial infection,23 or on
the skin of some frogs.24 In addition, often multiple HDPs act
at the same time and can exhibit synergism.25 However, for
peptides whose physiological concentrations are lower than
micromolar, other functions, such as immunomodulation,
might be more important than direct bacterial killing.1
The considerations that led to the prediction of a lower
bound for the active concentration, irrespective of the target
cell density, are very general, and therefore a similar behavior
could be conceived also for the toxic peptide activity against
host cells. To test this hypothesis, we extended our study to
erythrocytes, as a convenient model to investigate peptide
toxicity. Unfortunately, the high absorbance of the heme group
prevented us from determining peptide binding to RBCs with
the same spectroscopic approach used for bacteria.11 However,
we developed a protocol to measure hemolysis in the presence
of erythrocyte cell densities varying in a range of 4 orders of
magnitude. We observed a cell-density dependence of peptide
hemolytic activity similar to our findings for bacteria, with a
limiting value at low cell counts (Figure 2). From these data,
through a fitting with eq 2, an order of magnitude estimate can
be obtained for the partition constant and for the threshold of
bound peptides relative to the lysis of erythrocytes: Kapp
E ∼ 107
RBCs/mL and TE ∼ 107 molecules/RBC (the E super/
subscript indicates that these values refer to erythrocytes, rather
than to bacteria). Even if this determination of the parameters
is rather indirect, the estimate for the order of magnitude of
Kapp
E can be considered reliable, as it corresponds to the cell
density for which the minimum active concentration doubles
with respect to the limiting value at low cell counts (eq 2), and
the data of Figure 2 definitely indicate that this happens
between 4.5 × 106 and 4.5 × 107 cells/mL. In discussing these
findings, in comparison with the corresponding values for
bacteria, it should be considered that the membrane area of
RBCs is about 10 times that of E. coli cells but also that
different criteria were used to determine the bactericidal and
hemolytic concentrations (99.9% killing for MBC and 50%
hemolysis for HC50%). In addition, DNS-PMAP23 is a
particularly challenging system for testing HDP selectivity,
since this property was reduced with respect to the parent
peptide by the introduction of the fluorescent label.11,26 From
the standard activity assays commonly performed to determine
peptide activity and selectivity (see SI), we obtained for DNS-
PMAP23 a MIC of 16 μM and a concentration causing 50%
hemolysis (HC50%) of 29 μM, with a therapeutic index (i.e., the
ratio between the two values) of only 1.8. The Kapp values
obtained for the two cell types are compatible with this limited
selectivity. However, selectivity under realistic conditions would
depend on the cell densities of both cell types. To place these
data in context, it should be considered that the RBC density in
whole blood is on the order of 5 × 109 cells/mL.27 Therefore,
by comparing the data reported in Figures 1 and 2, and
extrapolating to the RBC density in blood, it would appear that
peptide concentration values might exist for which even the
Figure 2. Cell-density dependence of DNS-PMAP23 hemolytic
activity. (a) Curves of hemolytic activity determined in the presence
of different RBC densities. (b) Cell-density dependence of the peptide
concentration needed to cause 50% hemolysis (HC50%). The
continuous line is a fit with eq 2.
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marginally selective DNS-PMAP23 could be active, without
being toxic.
This conclusion rests on the assumption that separate assays
with one cell type only allow the prediction of the behavior in a
mixture of bacteria and host cells. However, the bactericidal
activity of the peptide might be inhibited due to sequestration
by the predominant host cells. A quantitative discussion of this
hypothesis, based on equilibrium equations similar to eq 2, is
reported in the SI. Indeed, the partition constants reported
above lead to the prediction that, when the RBC density
exceeds Kapp
E , significant inhibition of the bactericidal activity
should be observed. To test for this possibility, we developed a
novel assay to measure bacterial killing and RBC lysis in the
presence of both cell types (Figure 3). The conditions used
were of 4.5 × 107 E. coli cells/mL and 4.5 × 108 RBCs/mL.
Considering also the different size of the two cell types, these
values represent a large excess of eukaryotic versus bacterial cell
membranes. Rather surprisingly, we observed that the
antimicrobial activity was not affected by the presence of
RBCs (Figure 3a). Peptide toxicity, too, was the same in the
absence or in the presence of the bacteria.
The lack of alteration of the hemolytic activity in the
presence of bacteria is compatible with an equilibrium partition
treatment: due to the excess of RBCs, the fraction of peptide
bound to bacteria is negligible (see SI). By contrast, the peptide
capability to maintain its bactericidal activity also in the
presence of a large excess of erythrocytes contrasts with the
prediction based on partition equilibria between water and the
two cell types, since a large fraction of peptide molecules
should be sequestered by RBCs. Therefore, our finding
indicates that an equilibrium treatment is inadequate in the
presence of both host and bacterial cells, and that other effects
(such as a faster peptide binding to bacteria than to RBCs)
might be important. Of course, further experiments are needed
to clarify this point.
It is reasonable to assume that if the bactericidal activity of a
peptide with low selectivity like DNS-PMAP23 was unaffected
by the presence of erythrocytes, a more selective HDP would
also be insensitive to the simultaneous presence of both cell
types. To test this hypothesis, and to verify if our findings can
be generalized to other peptides, the killing and hemolysis
curves were measured for separated and mixed cell populations
also for esculentin-1a(1−21)NH2, abbreviated as Esc(1−21).
This peptide (sequence in Scheme 1) is a derivative of
esculentin-1a, a HDP isolated from the skin of the Pelophylax
lessonae/ridibundus frog, which has been demonstrated to be
highly selective, with a therapeutic index of 77 for E. coli.28,29
Also in this case, only a minor inhibition of the antibacterial
activity was caused by the presence of a large excess of RBCs
(Figure 3b). In addition, in contrast to what has been observed
for DNS-PMAP23, Esc(1−21) was highly active against
bacteria, without being significantly toxic in a large range of
concentrations. These results provide support for a possible
direct bactericidal function of HDPs under realistic conditions.
They also bode well for the possible therapeutic application of
HDPs, at least for topical treatments, while systemic
administration might be faced with other hurdles (sequestration
by serum components, proteolytic degradation, rapid clearance,
etc.). However, it should be noted that several reports exist
regarding the efficacy of HDPs in vivo30 and their ability to
concentrate at sites of infection.31
In conclusion, our findings can be summarized as follows: (i)
In the presence of one cell type only, the cell-density
dependence of the active peptide concentration is determined
by the peptide/cell binding equilibrium and can be predicted,
based on the determination of the apparent water/cell-
membrane partition constant and of the threshold of
membrane-bound peptides per cell needed to cause death.
(ii) At low cell densities, the MBC does not decrease below a
minimum limit, which in our case was in the micromolar range.
This finding begs the question whether these relatively high
concentrations can be reached in vivo. (iii) Since both the
peptide activity and toxicity depend on cell density, the effective
selectivity of HDPs depends on the amounts of host and target
cells present. (iv) At the same time, the antibacterial activity
was not affected by the contemporary presence of a large excess
of host cells, as could have been expected based on water/cell-
membrane partition equilibria. This finding indicates that a
reconsideration of the protocols and assays currently used in
the evaluation of HDP selectivity might be necessary. Extension
of the present results to other peptides and cell types is
essential, but due to the similarity of the properties of many
HDPs, our conclusions might apply also to other systems.
Note: While the present work was under revision, an article
by Wimley and co-workers was published online,32 reporting
the inhibition of the bactericidal activity of some HDPs by an
excess of RBCs. However, this effect was observed only when
the peptide was preincubated with RBCs before adding the
Figure 3. Bactericidal and hemolytic activities of DNS-PMAP23 (a)
and Esc(1−21) (b) in the presence of both bacteria and erythrocytes
or of one cell type only. 4.5 × 107 E. coli cells/mL, 4.5 × 108 RBCs/
mL.
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peptide/erythrocyte solution to bacteria. In agreement with our
findings, no significant inhibition took place when the peptide
was added directly to a bacteria/RBCs mixture. The fact that
bacterial killing depends on the order of addition of the various
components in the assay strongly supports the hypothesis that
kinetic effects might be important when different cell
populations are present at the same time.
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